GNH USA

Europe — EMA

Lamivudina E Zidovudina Aurobindo

GNH USA supplies Lamivudina E Zidovudina Aurobindo (Lamivudine/Zidovudine), a nucleoside reverse transcriptase inhibitor for HIV-1 treatment and prevention

Zidovudine, Lamivudine

Request sourcing

1
Pack/s

What is Zidovudine, Lamivudine?

Lamivudine and Zidovudine, the active ingredients in Lamivudina E Zidovudina Aurobindo, are nucleoside reverse transcriptase inhibitors presented as an oral dosage form for systemic use. They treat HIV‑1 infection in adults and adolescents and are used to prevent mother‑to‑child transmission of HIV.

GNH USA supplies Lamivudina E Zidovudina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Zidovudine, Lamivudine used for?

Lamivudine/Zidovudine is an antiretroviral combination that targets HIV replication. - HIV‑1 infection in adults and adolescents: reduces viral load and improves immune function when used as part of combination therapy. - Prevention of mother‑to‑child transmission of HIV: lowers the risk of vertical transmission when administered to pregnant women. - Chronic HIV management: maintains virologic suppression as part of a lifelong treatment regimen.

What are the side effects of Zidovudine, Lamivudine?

Both agents are generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient cranial pain. - Fatigue: general tiredness. - Anemia: reduced red blood cell count, especially with zidovudine. - Neutropenia: lowered neutrophil count. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Lactic acidosis: metabolic disturbance requiring immediate care. - Severe hepatotoxicity: liver enzyme elevations and jaundice. - Myopathy: muscle weakness and pain. - Pancreatitis: inflammation of the pancreas. - Stevens‑Johnson syndrome: severe skin reaction. - Bone marrow suppression: pancytopenia requiring monitoring.

What precautions apply to Zidovudine, Lamivudine?

Use of lamivudine/zidovudine requires careful clinical monitoring. - Pregnancy: Category C – weigh potential benefits against risks and consult obstetric specialist. - Breastfeeding: caution advised; drug may be excreted in milk. - Hepatic impairment: dose adjustment may be needed; monitor liver function tests. - Renal impairment: assess renal function regularly; adjust dosing if required. - Concomitant anemia or neutropenia: monitor blood counts closely. - Store at below 25°C: keep in original container, protect from moisture and direct sunlight.

What does Zidovudine, Lamivudine interact with?

Lamivudine/zidovudine may interact with several drug classes.

Major Interactions (Avoid): - Didanosine: increased risk of severe peripheral neuropathy and pancreatitis. - Stavudine: heightened mitochondrial toxicity. - Mycophenolate mofetil: reduced efficacy of antiretroviral therapy.

Moderate Interactions (Monitor Closely): - Trimethoprim‑sulfamethoxazole: additive bone marrow suppression. - Rifampicin: may lower plasma concentrations of zidovudine. - NSAIDs: potential for renal function impact when combined with tenofovir‑based regimens.

Frequently asked questions

What is Lamivudina E Zidovudina Aurobindo used for?+
Lamivudina E Zidovudina Aurobindo is a fixed‑dose combination of lamivudine and zidovudine used to treat HIV‑1 infection in adults and adolescents and to prevent mother‑to‑child transmission of HIV when given to pregnant women.
How do lamivudine and zidovudine work?+
Both drugs are nucleoside reverse transcriptase inhibitors. After oral absorption they are converted inside cells to active triphosphate forms that compete with natural nucleotides, become incorporated into viral DNA, and cause chain termination, thereby blocking HIV replication.
What is the usual dose of Lamivudina E Zidovudina Aurobindo?+
The prescribed dose is determined by the treating physician based on the patient’s clinical status, weight, renal and hepatic function, and concomitant medications. Patients should follow the exact regimen provided by their healthcare professional.
Is Lamivudina E Zidovudina safe during pregnancy or breastfeeding?+
The product is classified as Pregnancy Category C. It may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised during breastfeeding because the drugs can be excreted in breast milk; a healthcare provider should evaluate the risk‑benefit ratio.
How do I order Lamivudina E Zidovudina from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does this combination compare with other antiretroviral options?+
Lamivudine/zidovudine is a nucleoside reverse transcriptase inhibitor regimen that offers a well‑established efficacy profile and is often used in resource‑limited settings. Compared with newer agents such as integrase inhibitors, it may have a different side‑effect spectrum, including higher rates of anemia and neutropenia, but remains a cost‑effective option in many treatment guidelines.
What are the storage requirements for Lamivudina E Zidovudina?+
Store the product at temperatures below 25 °C in its original packaging. Protect it from moisture, direct sunlight and extreme heat to maintain stability and potency.
How is Lamivudina E Zidovudina administered?+
The medication is taken orally, usually with food or a glass of water, as directed by the prescribing clinician. Swallow tablets whole; do not crush or chew unless specifically instructed.
What are the most serious risks associated with this medication?+
Serious adverse events include lactic acidosis, severe hepatotoxicity, bone‑marrow suppression leading to pancytopenia, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these conditions.
Who should not use Lamivudina E Zidovudina?+
Patients with known hypersensitivity to lamivudine, zidovudine, or any excipients in the formulation should avoid the product. Those with severe anemia, neutropenia, or uncontrolled hepatic disease should be evaluated carefully before initiation.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Zidovudine, Lamivudine
Route
Oral Use
Manufacturer
Aurobindo Pharma (Italia) S.R.L.
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU